Check out all of the coverage of this year’s American Transplant Congress by eAJKD’s Dr. Vinay Nair below: Alemtuzumab Induction and Belatacept-Based Immunosuppression in Kidney Transplant Recipients Eculizumab Therapy for Chronic Antibody Mediated Rejection The Impact of Pre-donation Weight Loss on Post-donation Outcome Does Adding Rituximab to IVIg and Plasmapheresis Improve Outcome of AMR? 1-Yr […]
ATC 2013: Everolimus in Kidney Transplantation – HERAKLES trial
May 24, 2013 By Leave a Comment
Everolimus in Kidney Transplantation: HERAKLES trial Many studies have been conducted with the intention of reducing exposure to calcineurin inhibitors. Avoiding calcineurin inhibitors is expected to improve long term graft outcome by avoiding CNI nephrotoxicity. MTOR inhibitors (everolimus and sirolimus) have been used to minimize CNI exposure. Most studies reveal an improvement in GFR when […]
ATC 2013: Simultaneous Liver Kidney Transplantation – Stealing or Saving?
May 24, 2013 By Leave a Comment
Simultaneous Liver Kidney Transplantation: Stealing or Saving? That was the topic of a hotly debated 3 lecture session presented by Dr. Nadim from the University of Southern California, Dr. Charlton from Mayo Clinic, and Dr. Levitsky from Chicago. Audience members included nephrologists, hepatologists, and surgeons among others. Here are a few key points that I […]
ATC 2013: Development of De Novo HLA Antibodies After Transplantation – Results from the CTOT02 Study
May 23, 2013 By Leave a Comment
Development of De Novo HLA antibodies after transplantation: Results from the CTOT02 Study. CTOT02 is a large prospective multi-center trial set in 2 phases. Phase 1 involved screening of unsensitized patients 3-36 months post transplant every 3 months for the development of anti-HLA antibodies with a follow-up period of 60 months. Dr. Chandraker from Brigham […]
ATC 2013: Long-term Risk of ESRD in Kidney Donors – Is There Really No Harm?
May 23, 2013 By Leave a Comment
Long-term Risk of ESRD in Kidney Donors: Is There Really No Harm? One of the most shocking presentations in the ATC was given during the last plenary session. Dr. Muzaale from John Hopkins presented their analysis of ESRD risk in living donors compared to a matched healthy control population. So most of us quote several […]
ATC 2013: Everolimus in Liver Transplant Patients Preserves GFR. PROTECT Study – 35 Month Update
May 23, 2013 By Leave a Comment
Everolimus in liver transplant patients preserves GFR. PROTECT study – 35 month update. Long term exposure to calcineurin inhibitors (CNI) is nephrotoxic. It is believed that these drugs are therefore responsible for the significant number of patients with non-renal solid organ transplants that subsequently develop CKD. This was best seen in the NEJM paper by […]
ATC 2013: Does Adding Rituximab to IVIg and Plasmapheresis Improve Outcome of AMR? 1-Yr Results of RITUX-ERAH Study
May 23, 2013 By 1 Comment
Does adding rituximab to IVIg and plasmapheresis improve outcome of antibody mediated rejection? One year results of the RITUX-ERAH study. In transplant and nephrology, the use of rituximab has been increasing. Numerous papers have included it as a treatment for antibody mediated rejection (AMR) in the transplant literature; however, there are essentially no placebo controlled […]
ATC 2013: The Impact of Pre-donation Weight Loss on Post-donation Outcome
May 22, 2013 By 1 Comment
The Impact of Pre-donation Weight Loss on Post-donation Outcome. Dr. Marsden from Cardiff transplant unit, University of Wales, shared data on donor obesity from their living donor program during an abstract presentation at the ATC. Programs involved in clearing living kidney donors often have weight cutoffs for living kidney donors but the data on what […]
ATC 2013: Eculizumab Therapy for Chronic Antibody Mediated Rejection
May 22, 2013 By 1 Comment
Eculizumab Therapy for Chronic Antibody Mediated Rejection Chronic antibody mediated rejection (AMR) is currently a major problem in kidney transplantation. Chronic AMR results in poor graft survival and there are no effective therapies. To date the best data on treatment exists with rituximab and IVIg, although still limited. Eculizumab, a humanized monoclonal antibody against C5, […]
ATC 2013: Alemtuzumab Induction and Belatacept-Based Immunosuppression in Kidney Transplant Recipients
May 22, 2013 By 1 Comment
ATC abstract presentation: Alemtuzumab Induction and Belatacept-Based Immunosuppression in Renal Transplant Recipients: Peripheral Dynamics of T and B cell Populations with Potential Regulatory Signatures. In Monday’s session on Novel immunosuppressive agents, Dr. Xu of Emory University, presented his center’s data on using a combination of belatacept with sirolimus after alemtuzumab induction in kidney transplant recipients. […]
